췌장암 진단 시장 : 제품별, 검사 유형별, 암 유형별, 최종 용도별 - 세계 예측(2024-2032년)

The global pancreatic cancer diagnostic market will record 9.1% CAGR over 2024-2032, driven by the rising prevalence of pancreatic cancer. According to the World Health Organization, pancreatic cancer cases are expected to rise by 55% by 2030. Sedentary lifestyles and high-fat, low-fiber diets have contributed to this increase in cases, pushing the demand for advanced diagnostic tools. Innovations such as biomarker-based tests, liquid biopsies, and imaging techniques like endoscopic ultrasound and MRI have improved early detection rates, which is crucial given the aggressive nature of pancreatic cancer. These advancements enhance diagnostic accuracy and enable personalized treatment plans, increasing the demand for sophisticated tools.

Increased funding and investment in cancer research is also driving market growth. Governments and private organizations are investing heavily in developing and improving diagnostic methods. For instance, the National Cancer Institute allocated over $6 billion for cancer research in 2023. Public awareness campaigns about early diagnosis and regular screenings have led to higher patient participation in diagnostic procedures. Additionally, the growing elderly population, more susceptible to pancreatic cancer, underscores the need for advanced diagnostic solutions.

The overall pancreatic cancer diagnostic industry is classified based on product, test type, cancer type, end use, and region.

The biopsy segment is poised for significant traction through 2032, primarily due to their critical role in confirming the presence and stage of the disease. Biopsy tests, particularly fine-needle aspiration and core needle biopsies, provide definitive histopathological evidence necessary for accurate diagnosis. With advancements in imaging-guided biopsy techniques, the precision and safety of these procedures have significantly improved. Additionally, the growing emphasis on personalized medicine necessitates detailed genetic and molecular profiling of tumor tissues, which can only be obtained through biopsy samples.

The cancer research institutes segment is anticipated to hold a notable market share by 2032, due to focus on pioneering R&D initiatives. These institutes are at the forefront of discovering novel biomarkers, refining diagnostic techniques, and developing cutting-edge technologies that enhance early detection and diagnosis accuracy. By conducting extensive clinical trials and translational research, cancer research institutes facilitate the introduction of innovative diagnostic tools. Moreover, their collaborations with biotechnology firms and healthcare providers accelerate the adoption of these advanced diagnostics in clinical settings. The continual influx of research findings from these institutes not only drives technological advancements but also fosters an environment of ongoing improvement and adaptation in diagnostic practices.

Asia Pacific pancreatic cancer diagnostic industry will record a strong CAGR through 2032, driven by increasing healthcare expenditures, rising awareness of cancer diagnostics, and advancements in medical technology. There is a higher incidence rate of pancreatic cancer due to aging populations and lifestyle changes, prompting greater demand for effective diagnostic solutions. Additionally, government initiatives aimed at improving cancer care infrastructure and the presence of a burgeoning middle class with access to better healthcare services contribute to market expansion. The dynamic pharmaceutical and biotech sectors, coupled with a strong emphasis on R&D will further shape the regional market dynamics.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of pancreatic cancer
    • 3.2.1.2 Advancements in diagnostic technologies
    • 3.2.1.3 Growing healthcare expenditure globally
    • 3.2.1.4 Rising awareness regarding early cancer detection
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory scenarios
    • 3.2.2.2 High cost of diagnostic tests
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenario
• 3.5 Regulatory landscape
• 3.6 Technological landscape
  • 3.6.1 Core technologies
  • 3.6.2 Adjacent technologies
• 3.7 Pricing analysis, 2023
  • 3.7.1 By region
  • 3.7.2 By key player
• 3.8 Future market trends
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Instruments
• 5.3 Consumables

Chapter 6 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Imaging test
  • 6.2.1 CT scan
  • 6.2.2 MRI
  • 6.2.3 Ultrasound
  • 6.2.4 PET
  • 6.2.5 Other imaging tests
• 6.3 Biopsy
• 6.4 Blood test
  • 6.4.1 Liver function tests
  • 6.4.2 Tumor markers
  • 6.4.3 Other blood tests
• 6.5 Other test types

Chapter 7 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Exocrine
  • 7.2.1 Adenocarcinoma
  • 7.2.2 Squamous cell carcinoma
  • 7.2.3 Adenosquamous carcinoma
  • 7.2.4 Colloid carcinoma
• 7.3 Endocrine

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Diagnostic laboratories
• 8.4 Diagnostic imaging centers
• 8.5 Cancer research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 Agilent Technologies, Inc.
• 10.3 ASURAGEN, INC.
• 10.4 Becton, Dickinson and Company
• 10.5 BioMarker Strategies
• 10.6 Canon Inc.
• 10.7 Danaher Corporation
• 10.8 F. Hoffmann-La Roche Ltd.
• 10.9 GE HealthCare Technologies Inc.
• 10.10 Hitachi, Ltd.
• 10.11 Illumina, Inc.
• 10.12 Koninklijke Philips N.V.
• 10.13 Myriad Genetics, Inc.
• 10.14 Prestige Biopharma Limited (PBP)
• 10.15 QIAGEN N.V.
• 10.16 Siemens Healthineers AG
• 10.17 Sysmex Corporation
• 10.18 Thermo Fisher Scientific Inc.